Search | Page 6 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Myelodysplastic syndromes in older adults.

    ... Developments using the drugs lenalidomide , decitabine , and azacitidine have offered treatment options to ...

    Research Article last updated 10/11/2011 - 5:58pm.

  2. Current and future management options for myelodysplastic syndromes.

    ... such as lenalidomide , azacitidine and decitabine . Prior to these developments, supportive care measures ...

    Research Article last updated 10/11/2011 - 5:58pm.

  3. An update on the treatment of myelodysplastic syndromes.

    ... hypomethylating agents, azacitidine and decitabine , are approved for intermediate-2- and high-risk MDS. Trial ...

    Research Article last updated 10/11/2011 - 5:58pm.

  4. Pharmacotherapy of myelodysplastic syndromes.

    ... to the hypomethylating agents azacitidine and decitabine in non-del(5q) MDS patients remains at approximately 50%, ...

    Research Article last updated 10/11/2011 - 5:58pm.

  5. High-risk myelodysplastic syndromes: chemotherapy, transplantation, and beyond.

    ... ( azacitidine ) and 5-aza-2-deoxycytidine ( decitabine ), are both effective in high-risk MDS, but about 50% of ...

    Research Article last updated 10/11/2011 - 5:58pm.

  6. Practical recommendations for hypomethylating agent therapy of patients with myelodysplastic syndromes.

    ... approved in the United States-- azacitidine or decitabine --to patients with aggressive forms of myelodysplastic ...

    Research Article last updated 10/11/2011 - 5:58pm.

  7. Myelodysplastic syndromes.

    ... years. Lenalidomide , azacitidine , and decitabine are all FDA-approved agents to treat MDS; however, the only ...

    Research Article last updated 10/11/2011 - 5:58pm.

  8. Hypomethylating agents for the treatment of myelodysplastic syndromes

    ... 5-azacytidine (azacitidine) and 5-deoxyazacytidine ( decitabine ). Clinical trials of hypomethylating agents in MDS still raise a ...

    Research Article last updated 10/11/2011 - 5:58pm.

  9. Methylation of the p73 gene in patients with myelodysplastic syndromes: correlations with apoptosis and prognosis

    ... than that in the unmethylated group (p  =  0.094), decitabine treatment restored p73 expression and increased the level of ...

    Research Article last updated 11/05/2012 - 10:10am.

  10. Enhancing survival outcomes in the management of patients with higher-risk myelodysplastic syndromes.

    ... methyltransferase inhibitors azacitidine and decitabine . Recently, azacitidine demonstrated the ability to extend ...

    Research Article last updated 10/11/2011 - 5:58pm.